Casi Pharmaceuticals Inc Expected To Post A Loss Of 46 Cents A Share: Earnings Preview

CASI Pharmaceuticals

08/11/2022 19:32

* CASI Pharmaceuticals Inc  CASI.OQ   CASI.O  is expected
to show
a rise in quarterly revenue when it reports  results on November
10 (estimated). 
    * The Rockville Maryland-based  company is expected to
report  a
22.0% increase in revenue to $9.9 million from $8.11 million a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for CASI
Pharmaceuticals Inc
is for a loss of 46 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for CASI
Pharmaceuticals Inc is $21​, above​ its last closing price
of $1.98. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.64       -0.64      -0.56     Beat    12.5
 Mar. 31 2022  -1.02       -0.87      -0.60     Beat    30.8
 Dec. 31 2021              -0.57      -0.40     Beat    29.4​
 Sep. 30 2021  -0.55       -0.55      -0.70     Missed  -27.3
 ​​Jun.        -0.76       -0.72      -0.50     Beat    31
 30 2021                                                
 Mar. 31 2021  -0.61       -0.60      -1.10     Missed  -83.3​
 Dec. 31 2020              -0.70      -1.20     Missed  -71.4
 Sep. 30 2020  -0.55       -0.55      -1.40     Missed  -154.5
 This summary was machine generated November 8 at 19:31 GMT.  All
figures in US dollars  unless otherwise stated